JPRN-jRCT2043190090进行中（未招募）2 期
Multicenter, placebo-controlled, randomized, double-blind, parallel-group comparison study evaluating the safety and efficacy of SB-ADSC-01 in patients with spinocerebellar ataxia
Hashizume Atsushi0 个研究点目标入组 53 人开始时间: 2019年11月29日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 53
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Patients with SCA3 or SCA6 spinocerebellar ataxia whose diagnosis has been confirmed by genetic testing
- •(2) Patients whose SARA score is 5-15
- •(3) Patients whose age at the time of obtaining consent is 20 years or older (gender-independent)
- •(4) Patients who understand the consent explanation document and can consent to the document from the person
- •(5) Patients who can participate in clinical trials in compliance with the schedules and procedures described in the clinical trial protocol
排除标准
- •(1) Patients whose frequency and intensity of rehabilitation prior to obtaining consent cannot be maintained until the end of the trial
- •(2) Patients who are unable to keep the dosage and administration of tartyrelin hydrate and protyrelin tartrate hydrate in use before the consent is obtained until the end of the trial
- •(3) Pregnant women, lactating female patients, female patients who may be pregnant, female patients who wish to become pregnant during the study period, or male patients who wish to become pregnant partners
- •(4) Males and all fertile female patients who are unable to use appropriate contraceptive methods or obtain appropriate contraceptive consent from obtaining consent to the end of the trial *
- •*: Excluding those who have undergone permanent contraception and those after menopause (without menstruation for more than 12 months without another medical reason)
- •(5) History and complications of serious illnesses in critical organs including cardiac dysfunction, liver failure (eg, chronic cirrhosis), respiratory dysfunction and renal failure (hemodialysis or peritoneal dialysis) within 6 months before screening Patients with
- •(6) Patients with a history or complication of autoimmune disease (eg, systemic lupus erythematosus) affecting evaluation within 6 months before screening
- •(7) Patients with a history or complication of other neurological diseases (eg, amyotrophic lateral sclerosis) that affect evaluation within 6 months before screening
- •(8) Patients who received chemotherapy/radiotherapy within 5 years before screening
- •(9) Patients with a history or combination of malignant tumors
- •(10) Patients with hypersensitivity/allergy to products containing collagenase, dextran, dimethyl sulfoxide (DMSO), bovine or porcine components
- •(11) Patients with other mental disorders including dementia or disability depression, bipolar disorder, schizophrenia
- •(12) Patients with Beck Depression Inventory Second Edition (BDI-II) score of 21 points or more at a screening
- •(13) Patients who are currently participating in clinical trials of products such as pharmaceuticals, medical devices, and regenerative medicine, or other trial drugs, and 6 weeks from the administration of the trial drug to the start of administration of the trial product in this trial Or patients who have not passed a period of 10 times (whichever is longer) of the half-life (if the half-life of the investigational drug is known)
- •(14) Other patients who are judged to be inappropriate for study participation / participating physician
研究者
相似试验
进行中（未招募）
1 期
Study to gather information about proper dosing and safety of the oral FXIa inhibitor BAY 2433334 in patients following a recent non cardioembolic ischemic stroke which occurs when a blood clot has formed somewhere in the human body (but not in the heart) travelled to the brain.EUCTR2019-003431-33-ITBAYER AG1,800
进行中（未招募）
1 期
Study to gather information about proper dosing and safety of the oral FXIa inhibitor BAY 2433334 in patients following a recent non cardioembolic ischemic stroke which occurs when a blood clot has formed somewhere in the human body (but not in the heart) travelled to the brain.on-cardioembolic ischemic strokeMedDRA version: 22.1Level: LLTClassification code 10055221Term: Ischemic strokeSystem Organ Class: 100000004852MedDRA version: 21.1Level: LLTClassification code 10067625Term: Secondary preventionSystem Organ Class: 100000004865EUCTR2019-003431-33-FIBayer AG1,800
已完成
2 期
Multicenter, randomized, placebo-controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute non-cardioembolic ischemic strokestrokeNL-OMON55288Bayer50
进行中（未招募）
1 期
Study to gather information about proper dosing and safety of the oral FXIa inhibitor BAY 2433334 in patients following a recent non cardioembolic ischemic stroke which occurs when a blood clot has formed somewhere in the human body (but not in the heart) travelled to the brain.EUCTR2019-003431-33-PLBayer AG1,800
进行中（未招募）
1 期
Study to gather information about proper dosing and safety of the oral FXIa inhibitor BAY 2433334 in patients following a recent non cardioembolic ischemic stroke which occurs when a blood clot has formed somewhere in the human body (but not in the heart) travelled to the brain.on-cardioembolic ischemic strokeMedDRA version: 22.1Level: LLTClassification code 10055221Term: Ischemic strokeSystem Organ Class: 100000004852MedDRA version: 21.1Level: LLTClassification code 10067625Term: Secondary preventionSystem Organ Class: 100000004865EUCTR2019-003431-33-BGBayer AG1,800